This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGowan, P. M. Articles by Duffy, M. J. Search for Related Content PubMed PubMed Citation Articles by McGowan, P. M. Articles by Duffy, M. J.

ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression

Authors' Affiliations: ¹ Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital; ² University College Dublin School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin; and ³ Dublin Molecular Medicine Center, Dublin, Ireland

Requests for reprints: Michael J. Duffy, Department of Nuclear Medicine, St. Vincent's University Hospital, Dublin 4, Ireland. Phone: 353-1-2094378; Fax: 353-1-2696018; E-mail: michael.j.duffy{at}ucd.ie.

The ADAMs are a family of membrane proteins possessing a disintegrin and metalloprotease domain. One of their main functions is shedding of membrane proteins. The aim of this study was to test the hypothesis that ADAM-17 (also known as tumor necrosis factor- converting enzyme) is involved in breast cancer progression. Overexpression of ADAM-17 in MCF-7 breast cancer cells increased in vitro invasion and proliferation, whereas down-regulation of ADAM-17 expression in MDA-MB-435 cells decreased invasion and proliferation. At both mRNA and protein levels, ADAM-17 expression was significantly up-regulated in breast cancer compared with normal breast tissue. Using Western blotting, ADAM-17 protein in breast cancer was shown to exist in two forms migrating with approximate molecular masses of 100 and 120 kDa. Based on their known molecular mass, these bands were taken to represent the active and precursor forms of ADAM-17, respectively. The proportion of active to total ADAM-17 increased progressively from normal breast tissue to primary breast cancer to lymph node metastases (P = 0.017, Kruskal-Wallis test). In primary cancers, the active form was expressed more frequently in node-positive compared with node-negative tumors (P = 0.034, ² test). Furthermore, in primary carcinomas, both forms of ADAM-17 correlated significantly (Spearman correlation analysis) with levels of urokinase plasminogen activator (precursor form: r = 0.246, P = 0.032, n = 83 and active form: r = 0.428, P = 0.0001, n = 83) and proliferating cell nuclear antigen (precursor form: r = 0.524, P < 0.0001, n = 73 and active form: r = 0.365, P = 0.002, n = 73). Our results support the hypothesis that ADAM-17 is involved in breast cancer progression.

This article has been cited by other articles:

				K.-E. Kim, H. Song, C. Hahm, S. Y. Yoon, S. Park, H.-r. Lee, D. Y. Hur, T. Kim, C.-h. Kim, S. I. Bang, et al. Expression of ADAM33 Is a Novel Regulatory Mechanism in IL-18-Secreted Process in Gastric Cancer J. Immunol., March 15, 2009; 182(6): 3548 - 3555. [Abstract] [Full Text] [PDF]

				M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan Role of ADAMs in Cancer Formation and Progression Clin. Cancer Res., February 15, 2009; 15(4): 1140 - 1144. [Abstract] [Full Text] [PDF]